Need

neighgreasycornerΒιοτεχνολογία

14 Δεκ 2012 (πριν από 4 χρόνια και 10 μήνες)

208 εμφανίσεις

Conclusions from

Munich Round Table

on

European
MedTech

Research and Innovation

David Simpson

General Secretary EAMBES

Reader, Biomedical Signal Processing,

University of Southampton, UK

Munich Round Table 8 June, 2011

Introductions


What is
MedTech



Technology for disease prevention, screening, diagnosis
and for patient monitoring and treatment


Biomedical Engineering


Not biotechnology, genetic engineering, …


Munich Round Table


MedTech

EU Net


Technical University of Denmark


Participants from industry, academia, healthcare and

civil societies


Introductions


Who is EAMBES


European Alliance of Medical and Biological Engineering
and Science


Membership: 24 national and 5 trans
-
national societies

26 academic and research institutions;

representing some 8000 Biomedical Engineers in Europe


Who am I


General Secretary of EAMBES


Reader in Biomedical Signal Processing,

University of Southampton, UK

Research interests in cardiovascular

physiology/medicine,

physiotherapy and hearing

MedTech

in Europe


Addressing societal challenges through

European Research Cooperation


Challenges:


Ageing population, chronic illness or disability


Healthcare costs


Economic opportunities


MedTech

is part of the solution for Europe


Healthcare and quality of life


Economic potential
:



95 billion (
2009), 5
-
7% growth


8% reinvested in R&D


Job creation:


500 000 jobs


80
%
SMEs

Recommendations from Munich

1.
Adequate and sustainable funding strategy for
research and innovation

2.
Big societal challenges have small and medium
-
sized solutions

3.
Adding value by bringing together

4.
Fostering an innovation friendly environment

5.
Capacity building in neglected areas of research

6.
The missing mile in the healthcare innovation
cycle

1. Adequate and sustainable funding
strategy for research and innovation



Short funding cannot achieve full potential


Need for sustainable/renewable support over
longer periods


Need

uncomplicated calls in multidisciplinary
technologies for medicine/healthcare/life
sciences


Need

appropriate project

review processes that recognizes

Biomedical Engineering


2. Big societal challenges have small
and medium
-
sized solutions



Most novel medical technologies originate in
small and medium sized enterprises (SMEs)


SMEs are core for
MedTech


New technologies often go to start
-
ups, rather
than existing companies


Need

to support start
-
ups, which often
become SMEs.

3. Adding value by bringing together



Recommend clusters, with industry, health
-
care providers and research centres,
encouraging public
-
private partnerships


Need

to map state
-
of
-
the
-
art in
MedTech

in
Europe, identifying gaps, strengths and
opportunities

4. Fostering an innovation friendly
environment



Price
-
driven choices often do not consider
the entire value chain


The right technology in the

right place and time is

part of the solution


Need

innovation friendly

environment, with early

evaluation of innovation,

and simpler regulatory

frameworks

5. Capacity building in neglected areas
of research



Currently European
MedTech

focus is on IT
and diagnostics


Need

to support therapeutic technology
research

6. The missing mile in the healthcare
innovation cycle



Much European research is not well exploited
commercially in Europe


Often research results show promise in pre
-
clinical tests, but industrial funding becomes
available when clinical benefit / commercial
potential is more evident: THE MISSING MILE


Need

to support technologies further in the
development cycle

Recommendations

1.
Adequate and sustainable funding strategy for
research and innovation

2.
Big societal challenges have small and
medium
-
sized solutions

3.
Adding value by bringing together

4.
Fostering an innovation friendly environment

5.
Capacity building in neglected areas of
research

6.
The missing mile in the healthcare innovation
cycle